vs
Clearfield, Inc.（CLFD）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是Clearfield, Inc.的1.0倍（$35.5M vs $34.3M），Clearfield, Inc.净利率更高（-1.8% vs -304.2%，领先302.5%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -3.2%），Clearfield, Inc.自由现金流更多（$-2.4M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -3.5%）
Clearfield, Inc.总部位于美国明尼苏达州明尼阿波利斯市，是一家专注于光纤产品研发生产的企业，其产品主要应用于光纤通信网络建设领域，为通信基础设施部署提供相关硬件支撑。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CLFD vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.0倍
$34.3M
营收增速更快
RXRX
高出684.9%
-3.2%
净利率更高
CLFD
高出302.5%
-304.2%
自由现金流更多
CLFD
多$44.9M
$-47.3M
两年增速更快
RXRX
近两年复合增速
-3.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $34.3M | $35.5M |
| 净利润 | $-614.0K | $-108.1M |
| 毛利率 | 33.2% | 59.8% |
| 营业利润率 | -5.3% | -304.8% |
| 净利率 | -1.8% | -304.2% |
| 营收同比 | -3.2% | 681.7% |
| 净利润同比 | 67.8% | 39.6% |
| 每股收益（稀释后） | $-0.04 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLFDRXRX
| Q4 25 | $34.3M | $35.5M | ||
| Q3 25 | $23.4M | $5.2M | ||
| Q2 25 | $49.9M | $19.2M | ||
| Q1 25 | $47.2M | $14.7M | ||
| Q4 24 | $29.7M | $4.5M | ||
| Q3 24 | $5.6M | $26.1M | ||
| Q2 24 | $48.8M | $14.4M | ||
| Q1 24 | $36.9M | $13.8M |
净利润CLFDRXRX
| Q4 25 | $-614.0K | $-108.1M | ||
| Q3 25 | $-9.1M | $-162.3M | ||
| Q2 25 | $1.6M | $-171.9M | ||
| Q1 25 | $1.3M | $-202.5M | ||
| Q4 24 | $-1.9M | $-178.9M | ||
| Q3 24 | — | $-95.8M | ||
| Q2 24 | $-447.0K | $-97.5M | ||
| Q1 24 | $-5.9M | $-91.4M |
毛利率CLFDRXRX
| Q4 25 | 33.2% | 59.8% | ||
| Q3 25 | 53.2% | -183.8% | ||
| Q2 25 | 30.5% | -4.9% | ||
| Q1 25 | 30.1% | -48.0% | ||
| Q4 24 | 29.2% | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | 21.9% | 36.2% | ||
| Q1 24 | 7.7% | 19.1% |
营业利润率CLFDRXRX
| Q4 25 | -5.3% | -304.8% | ||
| Q3 25 | 10.3% | -3327.6% | ||
| Q2 25 | 3.0% | -916.8% | ||
| Q1 25 | 0.6% | -1297.9% | ||
| Q4 24 | -6.9% | -4042.4% | ||
| Q3 24 | — | -377.1% | ||
| Q2 24 | -4.7% | -697.4% | ||
| Q1 24 | -26.4% | -698.4% |
净利率CLFDRXRX
| Q4 25 | -1.8% | -304.2% | ||
| Q3 25 | -38.8% | -3135.3% | ||
| Q2 25 | 3.2% | -894.2% | ||
| Q1 25 | 2.8% | -1373.3% | ||
| Q4 24 | -6.4% | -3935.5% | ||
| Q3 24 | — | -367.5% | ||
| Q2 24 | -0.9% | -676.6% | ||
| Q1 24 | -16.0% | -662.4% |
每股收益（稀释后）CLFDRXRX
| Q4 25 | $-0.04 | $-0.17 | ||
| Q3 25 | $-0.65 | $-0.36 | ||
| Q2 25 | $0.11 | $-0.41 | ||
| Q1 25 | $0.09 | $-0.50 | ||
| Q4 24 | $-0.13 | $-0.56 | ||
| Q3 24 | — | $-0.34 | ||
| Q2 24 | $-0.04 | $-0.40 | ||
| Q1 24 | $-0.40 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $96.4M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $249.7M | $1.1B |
| 总资产 | $268.1M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资CLFDRXRX
| Q4 25 | $96.4M | $743.3M | ||
| Q3 25 | $106.0M | $659.8M | ||
| Q2 25 | $117.2M | $525.1M | ||
| Q1 25 | $112.0M | $500.5M | ||
| Q4 24 | $113.0M | $594.4M | ||
| Q3 24 | $129.0M | $427.6M | ||
| Q2 24 | $123.8M | $474.3M | ||
| Q1 24 | $142.9M | $296.3M |
总债务CLFDRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | $2.2M | $20.5M | ||
| Q2 24 | $2.1M | $22.9M | ||
| Q1 24 | — | — |
股东权益CLFDRXRX
| Q4 25 | $249.7M | $1.1B | ||
| Q3 25 | $256.2M | $1.0B | ||
| Q2 25 | $264.5M | $919.1M | ||
| Q1 25 | $265.9M | $933.9M | ||
| Q4 24 | $267.4M | $1.0B | ||
| Q3 24 | $275.8M | $524.6M | ||
| Q2 24 | $274.6M | $584.4M | ||
| Q1 24 | $279.2M | $401.2M |
总资产CLFDRXRX
| Q4 25 | $268.1M | $1.5B | ||
| Q3 25 | $306.2M | $1.4B | ||
| Q2 25 | $314.7M | $1.3B | ||
| Q1 25 | $310.9M | $1.3B | ||
| Q4 24 | $303.2M | $1.4B | ||
| Q3 24 | $315.3M | $726.5M | ||
| Q2 24 | $318.1M | $775.9M | ||
| Q1 24 | $315.4M | $557.8M |
负债/权益比CLFDRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | 0.01× | 0.04× | ||
| Q2 24 | 0.01× | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.4M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $-2.4M | $-47.3M |
| 自由现金流率自由现金流/营收 | -7.1% | -133.1% |
| 资本支出强度资本支出/营收 | 2.9% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流CLFDRXRX
| Q4 25 | $-1.4M | $-46.1M | ||
| Q3 25 | — | $-117.4M | ||
| Q2 25 | $7.9M | $-76.4M | ||
| Q1 25 | $3.0M | $-132.0M | ||
| Q4 24 | $7.2M | $-115.4M | ||
| Q3 24 | $22.2M | $-59.2M | ||
| Q2 24 | $4.0M | $-82.2M | ||
| Q1 24 | $-5.7M | $-102.3M |
自由现金流CLFDRXRX
| Q4 25 | $-2.4M | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | $7.5M | $-79.6M | ||
| Q1 25 | $654.0K | $-133.8M | ||
| Q4 24 | $5.1M | $-116.7M | ||
| Q3 24 | $18.2M | $-63.8M | ||
| Q2 24 | $2.8M | $-83.4M | ||
| Q1 24 | $-7.7M | $-109.0M |
自由现金流率CLFDRXRX
| Q4 25 | -7.1% | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | 15.1% | -413.9% | ||
| Q1 25 | 1.4% | -907.4% | ||
| Q4 24 | 17.1% | -2567.7% | ||
| Q3 24 | 323.0% | -244.6% | ||
| Q2 24 | 5.8% | -578.5% | ||
| Q1 24 | -20.8% | -789.9% |
资本支出强度CLFDRXRX
| Q4 25 | 2.9% | 3.5% | ||
| Q3 25 | 2.0% | 4.7% | ||
| Q2 25 | 0.8% | 16.4% | ||
| Q1 25 | 5.1% | 12.4% | ||
| Q4 24 | 7.0% | 28.6% | ||
| Q3 24 | 71.4% | 17.5% | ||
| Q2 24 | 2.5% | 8.2% | ||
| Q1 24 | 5.3% | 48.2% |
现金转化率CLFDRXRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.93× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
